…
Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Fortress Biotech, Inc. is a biopharmaceutical company that acquires, develops and seeks to commercialize prescription drugs and biologics through a portfolio of subsidiaries and strategic partnerships. Long-term growth may be driven by clinical progress and regulatory approvals across its pipeline, licensing or partnership deals, and commercialization of any approved products, which could support value realization across its diversified asset base.
Key risks include clinical and regulatory setbacks, substantial financing requirements that could lead to dilution, and operational complexity from managing multiple subsidiary programs.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -33.53M | -120.54M | -153.63M | -213.46M | -164.35M |
| Minority interest | 39.73M | 74.86M | 104.31M | 127.34M | -100.12M |
| Net income | 6.82M | -46.00M | -60.64M | -213.91M | -164.83M |
| Selling general administrative | 96.40M | 87.73M | 99.71M | 113.66M | 86.84M |
| Gross profit | 42.34M | 36.80M | 55.62M | 44.97M | 36.71M |
| Reconciled depreciation | 4.66M | 4.46M | 8.96M | 9.35M | 6.79M |
| Ebit | -24.83M | -108.95M | -139.24M | -202.26M | -179.00M |
| Ebitda | -20.16M | -104.49M | -131.17M | -200.86M | -178.35M |
| Depreciation and amortization | 4.66M | 4.46M | 8.07M | 1.40M | 0.65M |
| Non operating income net other | - | - | - | - | 24.19M |
| Operating income | -70.22M | -110.38M | -139.24M | -202.26M | -179.00M |
| Other operating expenses | 133.48M | 168.05M | 223.75M | 278.00M | 247.79M |
| Interest expense | 8.71M | 9.93M | 11.91M | 13.64M | 15.31M |
| Tax provision | -0.62M | 0.31M | 0.59M | 0.45M | 0.47M |
| Interest income | 2.48M | 2.68M | 2.98M | 1.40M | 0.65M |
| Net interest income | -7.62M | -10.84M | -15.02M | -12.24M | -14.66M |
| Non recurring | - | - | - | - | 15.62M |
| Income tax expense | -0.62M | 0.31M | 0.52M | 0.45M | 0.47M |
| Total revenue | 63.26M | 57.67M | 84.51M | 75.74M | 68.79M |
| Total operating expenses | 112.56M | 147.18M | 194.87M | 247.23M | 215.71M |
| Cost of revenue | 20.92M | 20.88M | 28.89M | 30.77M | 32.08M |
| Total other income expense net | 36.69M | -10.16M | -14.39M | -11.20M | 14.65M |
| Net income from continuing ops | -32.91M | -120.86M | -182.62M | -213.91M | -164.83M |
| Net income applicable to common shares | - | - | - | - | -64.70M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 185.55M | 144.22M | 167.53M | 294.30M | 396.50M |
| Intangible assets | 27.61M | 31.86M | 20.29M | 27.20M | 12.55M |
| Other current assets | 5.05M | 8.28M | 10.50M | 9.66M | 7.07M |
| Total liab | 123.36M | 145.87M | 165.94M | 244.28M | 170.63M |
| Total stockholder equity | 49.87M | 22.74M | 22.54M | 41.72M | 108.67M |
| Other current liab | 33.02M | 35.58M | 39.80M | 16.91M | 0.34M |
| Common stock | 0.03M | 0.03M | 0.01M | 0.11M | 0.10M |
| Capital stock | 0.03M | 0.03M | 0.02M | 0.11M | 0.10M |
| Retained earnings | -734.05M | -740.87M | -694.87M | -634.23M | -547.46M |
| Other liab | - | - | - | - | 2.03M |
| Other assets | - | - | - | - | 3.42M |
| Cash | 79.38M | 57.26M | 80.93M | 178.27M | 305.74M |
| Total current liabilities | 49.74M | 71.40M | 84.91M | 127.72M | 101.04M |
| Current deferred revenue | - | - | 0.84M | 0.73M | 2.61M |
| Net debt | -5.08M | 18.70M | 7.67M | -50.92M | -230.77M |
| Short term debt | 2.13M | 3.25M | 9.45M | 12.63M | 7.43M |
| Short long term debt | - | 0.62M | 3.00M | 10.18M | 5.32M |
| Short long term debt total | 74.30M | 75.96M | 88.59M | 127.34M | 74.98M |
| Other stockholder equity | 783.89M | 763.57M | 717.40M | 675.84M | 656.03M |
| Property plant equipment | - | - | - | - | 34.07M |
| Total current assets | 123.84M | 90.37M | 117.02M | 230.43M | 346.46M |
| Long term investments | 17.66M | 2.58M | - | - | 0.00M |
| Net tangible assets | - | - | - | - | 96.12M |
| Net receivables | 29.94M | 10.40M | 15.39M | 28.35M | 23.79M |
| Long term debt | 59.50M | 57.96M | 60.86M | 93.14M | 46.56M |
| Inventory | 9.62M | 14.43M | 10.21M | 14.16M | 9.86M |
| Accounts payable | 14.24M | 31.64M | 34.81M | 97.45M | 90.66M |
| Noncontrolling interest in consolidated entity | - | - | - | - | 117.20M |
| Accumulated other comprehensive income | - | - | -0.00M | - | - |
| Common stock total equity | - | - | - | - | 0.10M |
| Preferred stock total equity | - | - | - | - | 0.00M |
| Retained earnings total equity | - | - | - | - | -547.46M |
| Non currrent assets other | 1.62M | 3.32M | 4.28M | 3.66M | 3.42M |
| Non current assets total | 61.71M | 53.85M | 50.50M | 63.87M | 50.04M |
| Capital lease obligations | 14.80M | 17.37M | 20.80M | 24.02M | 23.09M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -15.00M | -2.43M | -22.93M | 56.86M |
| Change to liabilities | - | - | - | - | 46.35M |
| Total cashflows from investing activities | 10.12M | -15.00M | - | - | 40.51M |
| Net borrowings | -5.64M | -7.33M | - | - | -15.03M |
| Total cash from financing activities | 77.44M | 70.64M | 32.74M | 75.32M | 148.99M |
| Change to operating activities | - | - | - | - | -2.20M |
| Net income | -32.91M | -120.86M | -60.64M | -213.91M | -164.83M |
| Change in cash | 21.79M | -24.55M | -97.34M | -127.01M | 72.97M |
| Begin period cash flow | 58.81M | 83.36M | 178.27M | 307.96M | 235.00M |
| End period cash flow | 80.60M | 58.81M | 80.93M | 180.95M | 307.96M |
| Total cash from operating activities | -65.78M | -80.19M | -128.22M | -179.40M | -116.54M |
| Issuance of capital stock | 81.68M | 82.84M | 70.97M | 42.97M | 172.23M |
| Depreciation | 4.66M | 4.46M | 8.07M | 9.35M | 6.79M |
| Other cashflows from investing activities | 1.17M | - | - | - | -11.78M |
| Dividends paid | 0.66M | 4.71M | 8.77M | 8.78M | 8.78M |
| Change to inventory | 4.81M | -4.22M | 3.95M | 1.74M | -8.46M |
| Change to account receivables | -19.33M | 4.47M | 12.52M | -5.38M | 0.77M |
| Sale purchase of stock | -0.27M | 0.00M | -0.40M | -1.20M | 24.28M |
| Other cashflows from financing activities | -0.62M | -0.16M | -1.09M | 47.73M | -5.40M |
| Change to netincome | - | - | - | - | 20.32M |
| Capital expenditures | 0.00M | 15.00M | 8.10M | 3.06M | 16.35M |
| Change receivables | - | - | - | - | 0.83M |
| Cash flows other operating | - | - | - | - | -17.29M |
| Cash and cash equivalents changes | - | - | - | - | 72.97M |
| Change in working capital | -25.10M | -8.13M | -12.52M | -0.71M | 36.37M |
| Stock based compensation | 28.74M | 32.62M | 17.03M | 22.99M | 19.49M |
| Other non cash items | -41.17M | 11.71M | -88.05M | 2.89M | 24.43M |
| Free cash flow | -65.78M | -95.19M | -136.32M | -182.46M | -132.89M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| FBIO Fortress Biotech Inc |
-0.01 0.58% |
1.70 | - | 3.73 | 1.14 | 1.45 | 1.06 | -0.29 |
| NVO Novo Nordisk A/S |
-1.21 2.90% |
40.40 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-6.15 1.14% |
531.64 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
4.70 0.49% |
957.10 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154
781 652 4500
78
| Name | Title | Year Born |
|---|---|---|
| Dr. Lindsay Allan Rosenwald | Exec. Chairman, Pres & CEO | 1955 |
| Mr. Michael S. Weiss Esq. | Vice Chairman & Exec. Vice Chairman of Strategic Devel. | 1966 |
| Dr. George C. Avgerinos | Sr. VP of Biologics Operations | 1954 |
| Ms. Robyn M. Hunter | Exec. Officer | 1962 |
| Mr. David Jin | CFO & Head of Corp. Devel. | 1990 |
| Mr. Samuel Berry | Gen. Counsel & Corp. Sec. | NA |
| Dr. Thomas F. Schaible | Project Leader of Inflammatory Bowel Disease | NA |
| Dr. Lindsay Allan Rosenwald | Executive Chairman, President & CEO | 1955 |
| Mr. David Jin | CFO & Head of Corporate Development | 1991 |
| Mr. Michael S. Weiss Esq. | Executive Vice Chairman of Strategic Development & Director | 1966 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.